These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22215415)

  • 1. Identification of novel serological tumor markers for human prostate cancer using integrative transcriptome and proteome analysis.
    Han ZD; Zhang YQ; He HC; Dai QS; Qin GQ; Chen JH; Cai C; Fu X; Bi XC; Zhu JG; Liao DJ; Lu XP; Mo ZY; Zhu YP; Zhong WD
    Med Oncol; 2012 Dec; 29(4):2877-88. PubMed ID: 22215415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis.
    Jiang FN; He HC; Zhang YQ; Yang DL; Huang JH; Zhu YX; Mo RJ; Chen G; Yang SB; Chen YR; Zhong WD; Zhou WL
    PLoS One; 2013; 8(5):e63941. PubMed ID: 23737958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.
    Ummanni R; Mundt F; Pospisil H; Venz S; Scharf C; Barett C; Fälth M; Köllermann J; Walther R; Schlomm T; Sauter G; Bokemeyer C; Sültmann H; Schuppert A; Brümmendorf TH; Balabanov S
    PLoS One; 2011 Feb; 6(2):e16833. PubMed ID: 21347291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.
    Zhou L; Xia D; Zhu J; Chen Y; Chen G; Mo R; Zeng Y; Dai Q; He H; Liang Y; Jiang F; Zhong W
    Clin Transl Oncol; 2014 Oct; 16(10):906-13. PubMed ID: 24659377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Differentially Expressed Proteins in the Serum of Colorectal Cancer Patients Using 2D-DIGE Proteomics Analysis.
    Lim LC; Looi ML; Zakaria SZ; Sagap I; Rose IM; Chin SF; Jamal R
    Pathol Oncol Res; 2016 Jan; 22(1):169-77. PubMed ID: 26463353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer.
    Davalieva K; Kostovska IM; Kiprijanovska S; Markoska K; Kubelka-Sabit K; Filipovski V; Stavridis S; Stankov O; Komina S; Petrusevska G; Polenakovic M
    Prostate; 2015 Oct; 75(14):1586-600. PubMed ID: 26074449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
    Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
    Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker.
    Qian X; Li C; Pang B; Xue M; Wang J; Zhou J
    PLoS One; 2012; 7(5):e37225. PubMed ID: 22615945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
    Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
    J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
    Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
    Fang E; Zhang X; Wang Q; Wang D
    Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues.
    Sun W; Xing B; Sun Y; Du X; Lu M; Hao C; Lu Z; Mi W; Wu S; Wei H; Gao X; Zhu Y; Jiang Y; Qian X; He F
    Mol Cell Proteomics; 2007 Oct; 6(10):1798-808. PubMed ID: 17627933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
    Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY
    Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers.
    Ummanni R; Duscharla D; Barett C; Venz S; Schlomm T; Heinzer H; Walther R; Bokemeyer C; Brümmendorf TH; Murthy PV; Balabanov S
    J Proteomics; 2015 Apr; 119():218-29. PubMed ID: 25724726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis.
    Lin JF; Xu J; Tian HY; Gao X; Chen QX; Gu Q; Xu GJ; Song JD; Zhao FK
    Int J Cancer; 2007 Dec; 121(12):2596-605. PubMed ID: 17722004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of hepsin and inosine 5-monophosphate dehydrogenase 2 by siRNA reduces prostate cancer cells proliferation.
    A Wahab N; D Dardar H; Yunus R; M Zainudin Z; M Mokhtar N
    Malays J Pathol; 2022 Apr; 44(1):29-38. PubMed ID: 35484884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers.
    Zhang M; Chen L; Yuan Z; Yang Z; Li Y; Shan L; Yin B; Fei X; Miao J; Song Y
    Discov Med; 2016 Nov; 22(122):281-295. PubMed ID: 28009970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative proteomic study of human prostate cancer cells with different metastatic potentials.
    Li Q; Li Y; Wang Y; Cui Z; Gong L; Qu Z; Zhong Y; Zhou J; Zhou Y; Gao Y; Li Y
    Int J Oncol; 2016 Apr; 48(4):1437-46. PubMed ID: 26846621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.